Update on Embolization Therapies for Hepatocellular Carcinoma

Area of Science:

• Hepatobiliary oncology
• Interventional radiology
• Hepatocellular carcinoma (HCC) treatment

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern.
• Treatment strategies for HCC are guided by the Barcelona Clinic Liver Cancer (BCLC) staging system.
• Embolotherapy has traditionally been used for unresectable HCC.

Purpose of the Study:

• To review and summarize the latest applications of embolotherapy in HCC management.
• To analyze the role of embolotherapy across different BCLC stages (A-C).
• To highlight emerging embolization techniques and their potential benefits.

Main Methods:

• Literature review of recent studies on embolotherapy for HCC.
• Analysis of treatment applications based on BCLC staging.
• Synthesis of data on traditional and novel embolization techniques.

Main Results:

• Embolotherapy is increasingly used in earlier BCLC stages (A-C) as adjunct therapy, for bridging, downstaging, or improving resection safety.
• Novel applications like radioembolization (radiation segmentectomy) offer curative potential for unifocal disease.
• Transarterial chemoembolization (TACE) combined with portal vein embolization (PVE) or radiation lobectomy aids resection planning.
• Embolization shows promise in BCLC stage C, including combination with sorafenib, even with portal vein tumor thrombus.
• Limited prospective randomized controlled trial (RCT) data exist to definitively support superiority of one embolization technique over another.

Conclusions:

• Embolization therapies play a significant and expanding role in managing BCLC stages A-C HCC.
• Emerging embolization techniques offer new therapeutic avenues, including curative and palliative strategies.
• Patient-specific treatment decisions are crucial, though robust comparative data are limited.